SCHEMBL14246794

SCHEMBL14246794

CCCc1c(Cc2ccc(Cl)c(Cl)c2)c(=O)[nH]c2cc(O)cc(O)c12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
RNASEH1 O60930 1/20 0.38
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36
GPR84 Q9NQS5 2/20 0.36
HSD17B10 Q99714 2/20 0.35
TSHR P16473 1/20 0.35
PGAM1 P18669 1/20 0.35
ALKBH3 Q96Q83 2/20 0.35
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
POLH Q9Y253 1/20 0.34
IGF1R P08069 1/20 0.34
ALOX15 P16050 1/20 0.34
DAO P14920 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15931681 0.91 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDGPR84HSD17B10
SCHEMBL14246772 0.86 ALDH1A1 (0.43) ALDH1A1KDM4EHPGDALOX5MEN1
SCHEMBL15931674 0.82 KDM4E (0.44) ALDH1A1KDM4EHPGDGPR84HSD17B10
SCHEMBL14246763 0.78 PDE10A (0.43) ALOX5
SCHEMBL3345086 0.76 ALKBH3 (0.42) ALDH1A1KDM4EHPGDRNASEH1PTGES
SCHEMBL14246830 0.70 ALDH1A1 (0.46) ALDH1A1KDM4EPTGESALOX5ALKBH3
SCHEMBL15931677 0.70 KDM4E (0.47) ALDH1A1KDM4EGPR84HSD17B10TSHR
SCHEMBL15931675 0.70 PDE10A (0.42) HSD17B10TSHRMAPT
SCHEMBL14317221 0.68 ALDH1A1 (0.44) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL14246752 0.68 DAO (0.45) ALDH1A1KDM4EALOX5MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 ALDH1A1 1722/4885KDM4E 4656/4885HPGD 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.